Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer

Sandra Martínez-Canales, Miguel López de Rodas, Miriam Nuncia-Cantarero, Raquel Páez, Eitan Amir, B. Györffy, Atanasio Pandiella, Eva María Galán-Moya, Alberto Ocaña

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although early stage ovarian cancer is in most cases a curable disease, some patients relapse even with appropriate adjuvant treatment. Therefore, the identification of patient and tumor characteristics to better stratify risk and guide rational drug development is desirable. Using transcriptomic functional annotation followed by protein-protein interacting (PPI) network analyses, we identified functions that were upregulated and associated with detrimental outcome in patients with early stage ovarian cancer. Some of the identified functions included cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular stimuli or transcription regulation, among others. Genes within these functions included AURKA, AURKB, CDK1, BIRC5, or CHEK1 among others. Of note, the histone-lysine N-methyltransferase (EZH2) and the ubiquitin-conjugating enzyme E2C (UBE2C) genes were found to be upregulated and amplified in 10% and 6% of tumors, respectively. Of note, EZH2 and UBE2C were identified as principal interacting proteins of druggable networks. In conclusion, we describe a set of genes overexpressed in ovarian cancer with potential for therapeutic intervention including EZH2 and UBE2C.

Original languageEnglish
JournalCancer Medicine
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Ubiquitin-Conjugating Enzymes
Molecular Sequence Annotation
Ovarian Neoplasms
Aurora Kinase A
Genes
Proteins
Cell Division
Signal Transduction
Neoplasms
Cell Cycle
Recurrence
Therapeutics
Pharmaceutical Preparations

Keywords

  • Clinical outcome
  • Druggable proteins
  • EZH2
  • Ovarian cancer
  • Protein-protein interaction
  • UBE2C

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. / Martínez-Canales, Sandra; López de Rodas, Miguel; Nuncia-Cantarero, Miriam; Páez, Raquel; Amir, Eitan; Györffy, B.; Pandiella, Atanasio; Galán-Moya, Eva María; Ocaña, Alberto.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Martínez-Canales, Sandra ; López de Rodas, Miguel ; Nuncia-Cantarero, Miriam ; Páez, Raquel ; Amir, Eitan ; Györffy, B. ; Pandiella, Atanasio ; Galán-Moya, Eva María ; Ocaña, Alberto. / Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. In: Cancer Medicine. 2018.
@article{dcf5eacf10924caf899af4b64eeee8e3,
title = "Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer",
abstract = "Although early stage ovarian cancer is in most cases a curable disease, some patients relapse even with appropriate adjuvant treatment. Therefore, the identification of patient and tumor characteristics to better stratify risk and guide rational drug development is desirable. Using transcriptomic functional annotation followed by protein-protein interacting (PPI) network analyses, we identified functions that were upregulated and associated with detrimental outcome in patients with early stage ovarian cancer. Some of the identified functions included cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular stimuli or transcription regulation, among others. Genes within these functions included AURKA, AURKB, CDK1, BIRC5, or CHEK1 among others. Of note, the histone-lysine N-methyltransferase (EZH2) and the ubiquitin-conjugating enzyme E2C (UBE2C) genes were found to be upregulated and amplified in 10{\%} and 6{\%} of tumors, respectively. Of note, EZH2 and UBE2C were identified as principal interacting proteins of druggable networks. In conclusion, we describe a set of genes overexpressed in ovarian cancer with potential for therapeutic intervention including EZH2 and UBE2C.",
keywords = "Clinical outcome, Druggable proteins, EZH2, Ovarian cancer, Protein-protein interaction, UBE2C",
author = "Sandra Mart{\'i}nez-Canales and {L{\'o}pez de Rodas}, Miguel and Miriam Nuncia-Cantarero and Raquel P{\'a}ez and Eitan Amir and B. Gy{\"o}rffy and Atanasio Pandiella and Gal{\'a}n-Moya, {Eva Mar{\'i}a} and Alberto Oca{\~n}a",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1406",
language = "English",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer

AU - Martínez-Canales, Sandra

AU - López de Rodas, Miguel

AU - Nuncia-Cantarero, Miriam

AU - Páez, Raquel

AU - Amir, Eitan

AU - Györffy, B.

AU - Pandiella, Atanasio

AU - Galán-Moya, Eva María

AU - Ocaña, Alberto

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although early stage ovarian cancer is in most cases a curable disease, some patients relapse even with appropriate adjuvant treatment. Therefore, the identification of patient and tumor characteristics to better stratify risk and guide rational drug development is desirable. Using transcriptomic functional annotation followed by protein-protein interacting (PPI) network analyses, we identified functions that were upregulated and associated with detrimental outcome in patients with early stage ovarian cancer. Some of the identified functions included cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular stimuli or transcription regulation, among others. Genes within these functions included AURKA, AURKB, CDK1, BIRC5, or CHEK1 among others. Of note, the histone-lysine N-methyltransferase (EZH2) and the ubiquitin-conjugating enzyme E2C (UBE2C) genes were found to be upregulated and amplified in 10% and 6% of tumors, respectively. Of note, EZH2 and UBE2C were identified as principal interacting proteins of druggable networks. In conclusion, we describe a set of genes overexpressed in ovarian cancer with potential for therapeutic intervention including EZH2 and UBE2C.

AB - Although early stage ovarian cancer is in most cases a curable disease, some patients relapse even with appropriate adjuvant treatment. Therefore, the identification of patient and tumor characteristics to better stratify risk and guide rational drug development is desirable. Using transcriptomic functional annotation followed by protein-protein interacting (PPI) network analyses, we identified functions that were upregulated and associated with detrimental outcome in patients with early stage ovarian cancer. Some of the identified functions included cell cycle, cell division, signal transduction/protein modification, cellular response to extracellular stimuli or transcription regulation, among others. Genes within these functions included AURKA, AURKB, CDK1, BIRC5, or CHEK1 among others. Of note, the histone-lysine N-methyltransferase (EZH2) and the ubiquitin-conjugating enzyme E2C (UBE2C) genes were found to be upregulated and amplified in 10% and 6% of tumors, respectively. Of note, EZH2 and UBE2C were identified as principal interacting proteins of druggable networks. In conclusion, we describe a set of genes overexpressed in ovarian cancer with potential for therapeutic intervention including EZH2 and UBE2C.

KW - Clinical outcome

KW - Druggable proteins

KW - EZH2

KW - Ovarian cancer

KW - Protein-protein interaction

KW - UBE2C

UR - http://www.scopus.com/inward/record.url?scp=85044415396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044415396&partnerID=8YFLogxK

U2 - 10.1002/cam4.1406

DO - 10.1002/cam4.1406

M3 - Article

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -